{"protocolSection":{"identificationModule":{"nctId":"NCT02446977","nctIdAliases":["NCT02540980"],"orgStudyIdInfo":{"id":"JCS-CBG-2014-01"},"organization":{"fullName":"Castillo, José, M.D.","class":"INDIV"},"briefTitle":"Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke","officialTitle":"Randomized Clinical Trial to Investigate Whether Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke Causes a Reduction of Glutamate-mediated Excitotoxicity"},"statusModule":{"statusVerifiedDate":"2016-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-03"},"primaryCompletionDateStruct":{"date":"2015-12","type":"ACTUAL"},"completionDateStruct":{"date":"2015-12","type":"ACTUAL"},"studyFirstSubmitDate":"2015-04-21","studyFirstSubmitQcDate":"2015-05-13","studyFirstPostDateStruct":{"date":"2015-05-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-10-12","lastUpdatePostDateStruct":{"date":"2016-10-13","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Castillo, José, M.D.","class":"INDIV"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemic stroke to know if it causes a reduction of glutamate-mediated excitotoxicity.","detailedDescription":"The investigators hypothesis focuses on the effect of riboflavin given for the first three hours of ischemic stroke, as a reducing agent of cerebral glutamate concentration. This administration would produce a reduction of excitotoxic damage and consequently generate clinical improvement, while a lower income and a better functional outcome of patients at three months."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["ischemic","stroke","vitamin B2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":50,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Vitamin B2 Streuli®","type":"EXPERIMENTAL","description":"20mg IV","interventionNames":["Drug: Vitamin B2 Streuli®"]},{"label":"Solution for injection","type":"PLACEBO_COMPARATOR","description":"4ml IV","interventionNames":["Other: Solution for injection"]}],"interventions":[{"type":"DRUG","name":"Vitamin B2 Streuli®","description":"4ml IV","armGroupLabels":["Vitamin B2 Streuli®"],"otherNames":["CBG000592"]},{"type":"OTHER","name":"Solution for injection","description":"4ml IV","armGroupLabels":["Solution for injection"],"otherNames":["Placebo Comparator"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Reduction of serum glutamate concentration","description":"Difference between serum glutamate concentration from basal (prior to medication infusion) and levels at 3 ± 1 and 6 ± 1 hours, from administered medication, including branch CBG000592 (riboflavin/vitamin B2) and placebo.","timeFrame":"7 hours"}],"secondaryOutcomes":[{"measure":"Days of hospitalisation","description":"To study the average length of stay in patients with acute ischemic stroke: difference in days, between patient arrival and the patient's discharge, between the two treatment arms.","timeFrame":"3 months"},{"measure":"Percentage of clinical improvement (basal-high)","description":"To study the rate of clinical improvement in patients with acute ischemic stroke: clinical improvement according to the formula: (NIHSSbasal-NIHSSalta) / NIHSSbasal x 100 and compared between the two treatment arms.","timeFrame":"3 months"},{"measure":"Functional outcome using Rankin Scale at 90 days","description":"Study the functional outcome in patients with acute ischemic stroke: modified Rankin scale at 90 days, between two treatment arms.","timeFrame":"3 months"},{"measure":"Serum glutamate concentrations","description":"Variations of serum glutamate curves in patients with acute ischemic stroke between two branches: all concentrations of serum glutamate.","timeFrame":"7 hours"},{"measure":"Prognosis of patients using Rankin Scale at 90 days","description":"To explore the prognosis of patients without stroke, evaluating modified Rankin scale at 90 days.","timeFrame":"3 months"},{"measure":"Number of participants with Adverse Event","description":"Safety management: measuring adverse events throughout the study.","timeFrame":"3 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients older than 18 years, both men and women.\n2. Patient or legal representative able to understand and sign the informed consent.\n3. Patients with suspected stroke within 3 hours of onset.\n\nExclusion Criteria:\n\n1. Women of childbearing age, with potential for pregnancy or breastfeeding.\n2. Patients with a score ≥ 2 point 1a in the NIHSS scale.\n3. Scale pre-stroke modified Rankin ≥ 2.\n4. Inability to prior testing image needed for the study.\n5. Previous disorders that may interfere with the interpretation of neurological scales.\n6. Treatment with probenecid, tricyclic antidepressants, phenothiazines, streptomycin, erythromycin, tyrothricin, tetracyclines and carbomycin, at the time of inclusion.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"José Castillo, MD","affiliation":"Complejo Hospitalario Universitario de Santiago","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Complejo Hospitalario Universitario de Santiago","city":"Santiago de Compostela","state":"A Coruña","zip":"15706","country":"Spain","geoPoint":{"lat":42.88052,"lon":-8.54569}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000012256","term":"Riboflavin"}],"ancestors":[{"id":"D000014815","term":"Vitamins"},{"id":"D000018977","term":"Micronutrients"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000014803","term":"Vitamin B Complex"},{"id":"D000017319","term":"Photosensitizing Agents"},{"id":"D000003879","term":"Dermatologic Agents"}],"browseLeaves":[{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M21550","name":"Pharmaceutical Solutions","relevance":"LOW"},{"id":"M17236","name":"Vitamin B Complex","relevance":"LOW"},{"id":"M14775","name":"Riboflavin","asFound":"Reproductive Technology","relevance":"HIGH"},{"id":"M20699","name":"Micronutrients","relevance":"LOW"},{"id":"M16575","name":"Trace Elements","relevance":"LOW"},{"id":"M8308","name":"Folic Acid","relevance":"LOW"},{"id":"M19298","name":"Photosensitizing Agents","relevance":"LOW"},{"id":"M6764","name":"Dermatologic Agents","relevance":"LOW"},{"id":"T463","name":"Riboflavin","asFound":"Reproductive Technology","relevance":"HIGH"},{"id":"T470","name":"Vitamin B2","asFound":"Reproductive Technology","relevance":"HIGH"},{"id":"T5","name":"Glutamic Acid","relevance":"LOW"},{"id":"T446","name":"Folic Acid","relevance":"LOW"},{"id":"T448","name":"Folate","relevance":"LOW"},{"id":"T475","name":"Vitamin B9","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"Derm","name":"Dermatologic Agents"},{"abbrev":"Hemat","name":"Hematinics"},{"abbrev":"Vi","name":"Vitamins"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}